期刊
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 51, 期 2, 页码 453-457出版社
OXFORD UNIV PRESS
DOI: 10.1093/jac/dkg089
关键词
itraconazole; pharmacokinetics; omeprazole
资金
- NCRR NIH HHS [M01 RR000030-390700, M01 RR000030-420700, M01 RR000030-39S40700, M01 RR000030-380700, M01 RR000030-410700, M01 RR000030-40S20700, M01 RR000030-400700, M01-RR-30, M01 RR000030-40S10700, M01 RR000030] Funding Source: Medline
- NIAID NIH HHS [P0 AI44975, P01 AI044975] Funding Source: Medline
To determine the effect of omeprazole on peak serum concentrations (C-max) of itraconazole oral solution (IOS), we carried out a randomized, open-label, prospective, crossover study. Fifteen healthy, non-pregnant adults received a single dose of IOS 400 mg on two occasions, at least 7 days apart, with omeprazole 40 mg nightly for 7 days before either IOS dose 1 or 2. C-max, time to C-max (T-max) and AUC(0-8) were determined for itraconazole and its active metabolite, hydroxyitraconazole, for each dose and compared. Omeprazole did not significantly affect the C-max, T-max or AUC(0-8) of itraconazole or hydroxyitraconazole when administered as IOS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据